Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cel-Sci Corp (AMEX:CVM) (was HIV) -- Ignore unavailable to you. Want to Upgrade?

To: Tom Shutters who wrote (2233)	12/3/1998 8:55:00 AM
From: Thai Chung	Read Replies (1) \| Respond to of 2836

Thursday December 3, 8:30 am Eastern Time Company Press Release SOURCE: CEL-SCI Corporation CEL-SCI Corporation Announces Permission to Start Phase II Cancer Study in Hungary VIENNA, Va., Dec. 3 /PRNewswire/ -- CEL-SCI Corporation (Amex: HIV; Berlin Stock Exchange: LSR) announced today that the Hungarian National Institute of Pharmacy has given permission to start a clinical trial with CEL-SCI's immunotherapy drug Multikine™. The study will enroll 30 patients having squamous cell carcinoma of the head and neck. It will involve pretreatment with Multikine prior to surgery or radiation and is expected to be finished in the last quarter of 1999. Head and neck cancer is the sixth most frequently occurring cancer worldwide, with an incidence of 500,000 annually. Recent statistics show no reduction in head and neck cancer mortality, but rather a dramatic increase of the disease in certain segments of the population. This cancer is most frequently found in men in their 50's or early 60's with a history of smoking and alcohol consumption. Conventional treatment calls for either surgery, which can be extremely disfiguring, or radiation and chemotherapy, both of which are associated with very unpleasant side-effects. Multikine is a natural mixture of human immune system regulators called cytokines. It contains Interleukin-2 and other cytokines, several of which are being investigated individually as potential HIV-1 and cancer treatments. Multikine is currently in U.S., Canadian and Israeli clinical trials. CEL-SCI is a pioneer in the field of natural immunotherapy. The Company is developing immune-based treatments for cancer, AIDS, tuberculosis, malaria and herpes simplex. ''CEL-SCI press releases are available through Company News On-Call by fax, (800) 758-5804, Ext. 445563, or at prnewswire.com on the Internet.'' When used in this report, the words ''intend,'' ''believes,'' ''anticipated'' and ''expects'' and similar expressions are intended to identify forward-looking statements. Such statements are subject to risks and uncertainties which could cause actual results to differ materially from those projected. Factors that could cause or contribute to such differences include, an inability to duplicate the clinic results demonstrated in preclinical studies, timely development of any potential products that can be shown to be safe and effective, receiving necessary regulatory approvals, difficulties in manufacturing any of the Company's potential products and the risk factors set forth from time to time in CEL-SCI Corporation's SEC filings, including but not limited to its report on Form 10-K for the year ended September 30, 1997. The Company undertakes no obligation to publicly release the result of any revision to these forward-looking statements which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.